vs

Side-by-side financial comparison of First Savings Financial Group, Inc. (FSFG) and TherapeuticsMD, Inc. (TXMD). Click either name above to swap in a different company.

First Savings Financial Group, Inc. is the larger business by last-quarter revenue ($1.5M vs $893.0K, roughly 1.7× TherapeuticsMD, Inc.). On growth, TherapeuticsMD, Inc. posted the faster year-over-year revenue change (33.9% vs -0.7%). Over the past eight quarters, TherapeuticsMD, Inc.'s revenue compounded faster (68.9% CAGR vs -70.2%).

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

FSFG vs TXMD — Head-to-Head

Bigger by revenue
FSFG
FSFG
1.7× larger
FSFG
$1.5M
$893.0K
TXMD
Growing faster (revenue YoY)
TXMD
TXMD
+34.5% gap
TXMD
33.9%
-0.7%
FSFG
Faster 2-yr revenue CAGR
TXMD
TXMD
Annualised
TXMD
68.9%
-70.2%
FSFG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FSFG
FSFG
TXMD
TXMD
Revenue
$1.5M
$893.0K
Net Profit
$5.3M
Gross Margin
Operating Margin
Net Margin
350.2%
Revenue YoY
-0.7%
33.9%
Net Profit YoY
43.5%
-345.6%
EPS (diluted)
$0.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSFG
FSFG
TXMD
TXMD
Q4 25
$893.0K
Q3 25
$1.5M
$784.0K
Q2 25
$1.4M
$952.0K
Q1 25
$1.5M
$393.0K
Q4 24
$1.5M
$667.0K
Q3 24
$1.5M
$547.0K
Q2 24
$1.4M
$234.0K
Q1 24
$18.0M
$313.0K
Net Profit
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
$5.3M
$152.0K
Q2 25
$6.2M
$551.0K
Q1 25
$5.5M
$-653.0K
Q4 24
$6.2M
Q3 24
$3.7M
$-609.0K
Q2 24
$4.1M
$-1.1M
Q1 24
$4.9M
$-734.0K
Operating Margin
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
-109.9%
Q2 25
-73.0%
Q1 25
-221.6%
Q4 24
Q3 24
-207.3%
Q2 24
-1191.9%
Q1 24
32.1%
-364.9%
Net Margin
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
350.2%
19.4%
Q2 25
441.1%
57.9%
Q1 25
377.2%
-166.2%
Q4 24
424.0%
Q3 24
242.4%
-111.3%
Q2 24
295.8%
-465.8%
Q1 24
27.3%
-234.5%
EPS (diluted)
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
$0.76
$0.01
Q2 25
$0.88
$0.05
Q1 25
$0.79
$-0.06
Q4 24
$0.89
Q3 24
$0.53
$-0.05
Q2 24
$0.60
$-0.09
Q1 24
$0.72
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSFG
FSFG
TXMD
TXMD
Cash + ST InvestmentsLiquidity on hand
$31.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$193.5M
$26.9M
Total Assets
$2.4B
$37.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
$31.9M
Q2 25
$52.1M
Q1 25
$28.7M
$5.7M
Q4 24
$76.2M
$5.1M
Q3 24
$52.1M
Q2 24
$42.4M
Q1 24
$63.0M
Stockholders' Equity
FSFG
FSFG
TXMD
TXMD
Q4 25
$26.9M
Q3 25
$193.5M
$27.4M
Q2 25
$183.8M
$27.3M
Q1 25
$179.2M
$26.7M
Q4 24
$176.0M
$27.4M
Q3 24
$177.1M
$27.1M
Q2 24
$168.0M
$27.7M
Q1 24
$165.1M
$28.7M
Total Assets
FSFG
FSFG
TXMD
TXMD
Q4 25
$37.7M
Q3 25
$2.4B
$38.7M
Q2 25
$2.4B
$38.5M
Q1 25
$2.4B
$38.2M
Q4 24
$2.4B
$38.8M
Q3 24
$2.5B
Q2 24
$2.4B
$40.1M
Q1 24
$2.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSFG
FSFG
TXMD
TXMD
Operating Cash FlowLast quarter
$79.1M
$2.5M
Free Cash FlowOCF − Capex
$78.3M
FCF MarginFCF / Revenue
5199.5%
Capex IntensityCapex / Revenue
58.4%
Cash ConversionOCF / Net Profit
15.01×
TTM Free Cash FlowTrailing 4 quarters
$51.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSFG
FSFG
TXMD
TXMD
Q4 25
$2.5M
Q3 25
$79.1M
$999.0K
Q2 25
$6.5M
$381.0K
Q1 25
$-32.8M
$699.0K
Q4 24
$177.0K
$1.2M
Q3 24
$91.2M
$-71.0K
Q2 24
$-655.0K
$1.5M
Q1 24
$7.7M
$-229.0K
Free Cash Flow
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
$78.3M
Q2 25
$6.5M
Q1 25
$-32.9M
Q4 24
$-347.0K
Q3 24
$90.5M
Q2 24
$-702.0K
Q1 24
$7.7M
FCF Margin
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
5199.5%
Q2 25
462.7%
Q1 25
-2258.8%
Q4 24
-23.6%
Q3 24
5974.9%
Q2 24
-51.0%
Q1 24
42.6%
Capex Intensity
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
58.4%
Q2 25
0.5%
Q1 25
8.7%
Q4 24
35.7%
Q3 24
45.1%
Q2 24
3.4%
Q1 24
0.0%
Cash Conversion
FSFG
FSFG
TXMD
TXMD
Q4 25
Q3 25
15.01×
6.57×
Q2 25
1.05×
0.69×
Q1 25
-5.97×
Q4 24
0.03×
Q3 24
24.84×
Q2 24
-0.16×
Q1 24
1.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons